Compare Cassava Sciences Inc (FLNA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Prospect Capital Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Prospect Capital Corporation trades at $2.31 (market cap $1.14B). The key difference: Prospect Capital Corporation is far larger — about 21.5× Cassava Sciences Inc's market cap, and Prospect Capital Corporation pays a 22.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PSEC | |
|---|---|---|
Market Cap | $53.14M | $1.14B |
Sector | Health | Financials |
52-Week High | $4.64 | $3.47 |
52-Week Low | $1.09 | $2.15 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
PSEC trades at $2.295, up 1.1% today, with a neutral technical signal and bearish moving averages. The stock shows a low P/B of 0.39 but negative revenue and net income in 2025. Recent earnings beats and consistent dividends highlight income potential, though financial performance remains volatile with a -495.94% net income margin. News includes a new investment in ShipOffers and the sale of Valley Electric.
Outlook is mixed: deep discount to NAV and high yield appeal to income seekers, but persistent financial deterioration and analyst skepticism pose risks. Upside depends on portfolio stability and NAV recovery, while downside risks include further dividend cuts and economic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
